Drug Combination Details
General Information of the Combination (ID: C95896) | |||||
---|---|---|---|---|---|
Name | Cyclopamine NP Info | + | TNF-related apoptosis inducing ligand Drug Info | ||
Structure | + | ||||
Disease |
Stomach cancer
[ICD-11: 2B72]
|
Investigative | [1] | ||
Multiple myeloma
[ICD-11: 2A83]
|
Investigative | [2] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. Enhancing Drug Efficacy by This Combination | ||||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [2] | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | Gli1 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | SKO-007 | CVCL_4974 | Plasma cell myeloma | Homo sapiens | ||
RPMI-8226 | CVCL_0014 | Plasma cell myeloma | Homo sapiens | |||
Experimental
Result(s) |
Combination of cyclopamine and CPT exhibited synergistic effects on the inhibition of proliferation and induction of apoptosis in myeloma cells. | |||||
β. Reversing Drug Resistance by This Combination | ||||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [1] | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
|
Experimental
Result(s) |
Cyclopamine sensitizes TRAIL-resistant gastric cancer cells to TRAIL-induced apoptosis via endoplasmic reticulum stress-mediated increase of death receptor 5 and survivin degradation. |